Inhibitors of histone deacetylase
Disclosed are compounds of formula I that inhibit histone deacetylase (HDAC) enzymatic activity, pharmaceutical compositions comprising such compounds, as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC, wherein A, W, W 1 , W 2 , Ar 2 , and G are described herein.
1. A compound of formula I:
wherein
and the ring containing W 1 and W to which it is fused together form an optionally substituted 1,3,4,9-tetrahydro-2H-b-carbolin-2-yl or an optionally substituted 1,3,4,4a,9,9a-hexahydro-2H-b-carbolin-2-yl substituent;
W 2 is a bond or [—C(R 1 )(R 2 )—] p ;
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
p is 1, 2, 3 or 4;
wherein Ar 2 -G-C(O)NHOH, is 5-[-G-C(O)NHOH]-pyrimid-2-ylene
G is a bond; or
a tautomer, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein W 2 is a bond.
3. The compound according to claim 2 , wherein said compound is:
[N-hydroxy-2-(1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-fluoro-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(6-fluoro-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(6-benzyloxy-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(6-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-{6-[3-(morpholin-4-ylmethyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{6-[3-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{6-[4-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{6-[2-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{9-[2-pyrrolidin-1-ylethyl]-1,3,4,9-tetrahydro-2H-b- carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-[9-(2-piperidin-1-ylethyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],
[N-hydroxy-2-[9-(2-morpholin-4-ylethyl)-1,3,4,9-tetrahydro-2H-b- carbolin-2-yl]pyrimidine-5-carboxamide],
[N-hydroxy-2-[9-(phenylsulfonyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],
[N-hydroxy-2-(9-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(9-benzyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],
[2-(9-acetyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)-N-hydroxypyrimidine-5-carboxamide],
[N-hydroxy-2-{9-[2-pyrrolidin-1-ylmethyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-[9-(2-hydroxyethyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],
[N-hydroxy-2-[9-(1-methylpiperidin-3-yl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide] or
[N-hydroxy-2-(6-methyl-1,3,4,4a,9,9a-hexahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide].
4. A compound of formula I:
wherein
and the ring containing W 1 and W to which it is fused together form an optionally substituted 1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl or an optionally substituted 1,1a,3,4,4a,5-hexahydro-2H-pyrido[4,3-b]indol-2-yl substituent;
W 2 is a bond or [-C(R 1 )(R 2 )—] p ;
R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;
p is 1, 2, 3 or 4;
wherein Ar 2 -G-C(O)NHOH, is 5-[-G-C(O)NHOH]-pyrimid-2-ylene G is a bond; or
a tautomer, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.
5. The compound according to claim 4 , wherein W 2 is a bond.
6. The compound according to claim 5 , wherein said compound is:
[N-hydroxy-2-(1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[2-(8-chloro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)-N-hydroxypyrimidine-5-carboxamide],
[2-(8-bromo-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)-N-hydroxypyrimidine-5-carboxamide],
[N-hydroxy-2-[8-(trifluoromethoxy)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl]pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-phenyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide].
[N-hydroxy-2-(8-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-methoxy-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7,8-dimethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-chloro-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(7-bromo-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-trifluoromethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(9-chloro-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-nitro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide].
[N-hydroxy-2-(8-(N-acetamido)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-(N-methylsulfonamido)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-amino-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-isopropyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-tert-butyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{7-phenyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{5-acetyl-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-(8-methyl-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide] or
[N-hydroxy-2-{8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide].
7. The compound according to claim 4 , wherein said compound is:
[N-hydroxy-2-{8-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-(pyridin-3-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-(pyrimidin-5-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(morpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(piperidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N,N-dimethylaminomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-((4-hydroxymethylpiperidin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(thiomorpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N,N-di(2-hydroxyethyl)aminomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(piperazin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-((4-acetylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-(morpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-(thiomorpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-(hydroxymethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[5-((4-methylpiperazin-1-yl)methyl)-2-furyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[5-(morpholin-4-yl)methyl-2-furyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[5-((4-methylpiperazin-1-yl)methyl)-thien-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(hydroxymethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-methoxyphenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-methylphenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-(N-acetamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-(fur-2-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(pyrrolidin-1-ylcarbonyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{7-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-aminophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-fluorophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-fluorophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[fur-3-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[1H-pyrrol-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(methylthio)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[4-dimethylaminophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(methylsulfinyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N-acetamidomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N-methylsulfonamidomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N-acetamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(N-methylsulfonamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],
[N-hydroxy-2-{8-[3-(1H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide] or
[N-hydroxy-2-{8-[thien-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide].
8. A pharmaceutical composition comprising an effective amount of one or more compounds according to claim 1 or claim 4 and a pharmaceutically inert carrier.